Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeriesTORONTO and DALLAS, July 2, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced today that Medical City Dallas Hospital, an award-winning 899-bed acute care hospital in the Dallas-Fort Worth area, has adopted the company's current S-Series OCT (optical coherence tomog ...

Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate and largely related to injection site and infusion reactions with no serious or severe adverse events observedFollowing a single dose, serum concentrations of VYD2311 remained high at six months with an observed half-life of the IM dose route having the longest duration at 76.0 (CI: 68.5 – 90.7) days Comprehensive ...

HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (“Itafos” or “the Company”) today announces that the OTC Markets Group Inc., operator of regulated markets for trading 12,000 US and international securities, has approved the Company’s application to trade on the OTCQX® Best Market, upgrading from the Pink® market. Itafos will begin trading today on the OTCQX under the symbol “ITFS”. Trading on the OTCQX Best Market offers Itafos an efficient, cost-effective way to access th ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced ITAFOS INC. (TSX-V: IFOS; OTCQX: ITFS), a phosphate and specialty fertilizer company, has qualified to trade on the OTCQX® Best Market. ITAFOS INC. upgraded to OTCQX from the Pink® market. ITAFOS INC. begins trading today on OTCQX under the symbol “ITFS.” U.S. investors can find current financial disclosure and Real-Time Level 2 ...

Company Overview - Itafos Inc. is a phosphate and specialty fertilizer company headquartered in Houston, Texas, and trades on the TSX-V under the ticker symbol "IFOS" [3] - The principal shareholder of the company is CL Fertilizers Holding LLC, an affiliate of Castlelake, L.P., a global private investment firm [3] Annual General Meeting Highlights - All items of business were approved at the annual general meeting of shareholders held on June 18, 2025 [1] - Six incumbent directors were overwhelmingly re-elected: Anthony Cina, Ricardo De Armas, G. David Delaney, Ronald Wilkinson, Stephen Shapiro, and Isaiah Toback [1] Auditor Appointment - The appointment of PricewaterhouseCoopers LLP as the Company's auditor was ratified by shareholders [2] Production Capacity - The company operates several vertically integrated phosphate fertilizer businesses with significant production capacities: - Conda, Idaho, US: approximately 550kt per year of various phosphate products and 27kt per year of hydrofluorosilicic acid [7] - Arraias, Tocantins, Brazil: approximately 500kt per year of single superphosphate and 40kt per year of excess sulfuric acid [7] - Farim, Guinea-Bissau: a high-grade phosphate mine project [7] - Santana, Pará, Brazil: a vertically integrated high-grade phosphate mine and fertilizer plant project [7]

克雷西 发自 凹非寺 量子位 | 公众号 QbitAI o3-pro刚刚也挑战了这两款游戏，而且表现还都不错，直接 突破了benchmark上限 。 具体来说，benchmark中推箱子一共就只做到了被o3-pro突破的第六关；俄罗斯方块则是强行终止的结果，实际上o3-pro根本停不下来。 如果和前SOTA——o3比较，o3-pro的成绩也是直接翻倍。 还有网友直言，比起大模型竞技场，这套标准才更适合做测试大模型的基准。 经典小游戏成为新Benchmark 推箱子、俄罗斯方块……这些人类的经典怀旧小游戏，也成大模型benchmark了。 o3-pro挑战的这两个游戏，出自一套名为 Lmgame 的benchmark，顾名思义就是让大模型玩游戏。 o3-pro挑战的推箱子是从1989年的版本修改而来，在o3-pro之前，评估指标是游戏结束之前推动到目标位置的箱子总数。 不过这次o3-pro直接把所有关卡都通了，颇有种"得一百分是因为卷面只有一百分"的感觉。 但也不必担心，测试基准会动态更新，GItHub仓库中半个月前更新的游戏地图还只有四关，原版游戏更是有足足50多个关卡。 而在o3-pro挑战之前，表现最好的 ...

克雷西 发自 凹非寺 量子位 | 公众号 QbitAI 推箱子、俄罗斯方块……这些人类的经典怀旧小游戏，也成大模型benchmark了。 o3-pro刚刚也挑战了这两款游戏，而且表现还都不错，直接 突破了benchmark上限 。 还有网友直言，比起大模型竞技场，这套标准才更适合做测试大模型的基准。 经典小游戏成为新Benchmark o3-pro挑战的这两个游戏，出自一套名为 Lmgame 的benchmark，顾名思义就是让大模型玩游戏。 o3-pro挑战的推箱子是从1989年的版本修改而来，在o3-pro之前，评估指标是游戏结束之前推动到目标位置的箱子总数。 具体来说，benchmark中推箱子一共就只做到了被o3-pro突破的第六关；俄罗斯方块则是强行终止的结果，实际上o3-pro根本停不下来。 如果和前SOTA——o3比较，o3-pro的成绩也是直接翻倍。 不过这次o3-pro直接把所有关卡都通了，颇有种"得一百分是因为卷面只有一百分"的感觉。 但也不必担心，测试基准会动态更新，GItHub仓库中半个月前更新的游戏地图还只有四关，原版游戏更是有足足50多个关卡。 而在o3-pro挑战之前，表现最好的 ...

HOUSTON, June 06, 2025 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that it will present at the Sidoti Small Cap Conference at 4:00 PM EDT on Thursday, June 12, 2025. Register here to attend the virtual event: https://loom.ly/AeaJJ7o. About Itafos The Company is a phosphate and specialty fertilizer company. The Company’s businesses and projects are as follows: Conda – a vertically integrated phosphate fertilizer business located in Idaho, US, with the following production ca ...

Core Insights - Invivyd, Inc. announced the publication of results from its CANOPY Phase 3 clinical trial of pemivibart, demonstrating its safety and efficacy for the prevention of symptomatic COVID-19 in a contemporary U.S. population facing immune-evasive Omicron variants [1][4][6] Group 1: Clinical Trial Overview - The CANOPY Phase 3 clinical trial randomized 788 adult participants across 18 sites, focusing on immunocompromised individuals and those at risk due to regular face-to-face interactions [2][8] - The trial met all primary and exploratory endpoints during a significant COVID-19 transmission period in the U.S. from September 2023 to September 2024 [2][8] - Pemivibart showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months [4][6] Group 2: Safety and Tolerability - Pemivibart was generally well-tolerated, with most adverse events classified as mild to moderate [3][6] - The most common treatment-emergent adverse events included infusion-related reactions, with a low incidence of anaphylactic reactions (0.6%) [3][12] - The safety profile aligns with previous clinical trials for COVID-19 monoclonal antibodies [3][6] Group 3: Regulatory and Future Implications - The trial's results support the emergency use authorization (EUA) of PEMGARDA (pemivibart) for pre-exposure prophylaxis in certain immunocompromised patients [2][10] - The publication aims to educate clinicians on the potential of monoclonal antibodies in combating COVID-19, particularly for immunocompromised individuals [5][7] - Invivyd plans to leverage data from the CANOPY trial to expedite the approval of novel antibodies like VYD2311 [7][18]

Core Insights - Invivyd, Inc. announced that its investigational monoclonal antibody PEMGARDA (pemivibart) has been included in the NCCN Clinical Practice Guidelines for B-Cell Lymphomas, recognizing its potential for pre-exposure prophylaxis against COVID-19 in immunocompromised patients [1][2][3] Group 1: Product Development and Approval - PEMGARDA is recognized as a potential option for pre-exposure prophylaxis against COVID-19 in patients with B-cell malignancies, particularly those who may not respond adequately to vaccination [2][3] - The monoclonal antibody is engineered to retain activity against circulating SARS-CoV-2 variants and is currently authorized under Emergency Use Authorization (EUA) from the U.S. FDA for certain patients [3][6] - The NCCN's recommendation is based on the unmet need in patients with B-cell lymphomas, who are at elevated risk for COVID-19-related complications [3][4] Group 2: Clinical Implications - The inclusion of PEMGARDA in the NCCN Guidelines provides clinicians with a valuable tool to protect vulnerable patients from COVID-19, allowing them to continue their cancer care [3][4] - The updated NCCN Guidelines reflect growing clinical and real-world evidence supporting the use of passive immunization to complement vaccination strategies in high-risk oncology populations [4] Group 3: Company Overview - Invivyd, Inc. is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, starting with SARS-CoV-2 [13] - The company utilizes a proprietary integrated technology platform designed to assess, monitor, develop, and adapt to create best-in-class antibodies [13]